Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBGWPH)

• Drug Name: Medroxyprogesterone Drug Info
• Synonyms: Asconale; Colirest; Hematrol; Hydroxymethylprogesterone; Lunelle; Medrossiprogesterone; Medroxiprogesterona; Medroxiprogesteronum; Medroxyprogesteron; Medroxyprogesteronum; Methylhydroxyprogesterone; Adgyn Medro; Farlutal inyectable; Medroprogesterone Acetate; Medrossiprogesterone [DCIT]; Medroxyprogesteron acetate; Medroxyprogesterone Strakan Brand; Sodelut G; Strakan Brand of Medroxyprogesterone; MPA Gyn 5; U 8840; CBP-1011; Farlutal inyectable (TN); G-Farlutal; Medroxiprogesterona [INN-Spanish]; Medroxyprogesterone (INN); Medroxyprogesterone [INN:BAN]; Medroxyprogesteronum [INN-Latin]; Novo-Medrone; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-(9CI); Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)-(9CI); (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; (6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione; 17 alpha Hydroxy 6 alpha Methylprogesterone; 17 alpha-Hydroxy-6 alpha-Methylprogesterone; 17-Hydroxy-6.alpha.-methylprogesterone; 17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione; 17-Hydroxy-6alpha-methylprogesterone; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone; 17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 17alpha-Hydroxy-6alpha-methylprogesterone; 6-Dihydromegestrol; 6-alpha-Methyl-17-alpha-hydroxyprogesterone; 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone; 6alpha-Methyl-17alpha-hydroxyprogesterone; 6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione; 6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione
• Therapeutic Class: Contraceptive Agents
• Cross-matching ID:
  PubChem CID: 10631
  ChEBI ID: CHEMBL1390
  CAS Number: CAS 520-85-4
  TTD Drug ID: D0I2SD
  INTEDE Drug ID: DR1012

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
GnRH signaling pathway	2.08	0.00e+0	80/93 (86.02%)	GNAS;CALML3;CALML5;...
Glucagon signaling pathway	1.99	0.00e+0	89/107 (83.18%)	GNAS;CALML3;CALML5;...
Biosynthesis of unsaturated fatty acids	1.97	3.97e-3	21/27 (77.78%)	FADS2;SCD;HACD3;...
Salivary secretion	1.93	2.98e-3	76/93 (81.72%)	GNAS;CALML3;CST1;...
Insulin signaling pathway	1.91	2.38e-3	121/137 (88.32%)	FASN;CALML3;CALML5;...
Melanogenesis	1.85	1.59e-2	74/101 (73.27%)	GNAS;CALML3;CALML5;...
Steroid biosynthesis	1.84	1.70e-2	19/20 (95%)	DHCR7;NSDHL;TM7SF2;...
Phototransduction	1.84	1.49e-2	21/29 (72.41%)	CALML3;CALML5;GNB1
Histidine metabolism	1.78	2.78e-2	16/22 (72.73%)	ALDH2;ALDH3A2;AOC1;...
Fatty acid elongation	1.76	3.45e-2	19/27 (70.37%)	HACD3;ELOVL4;ELOVL5;...
Estrogen signaling pathway	1.76	3.25e-2	119/137 (86.86%)	GNAS;CALML3;ESR1;...
Amoebiasis	1.75	3.18e-2	99/102 (97.06%)	GNAS;ACTN1;GNAL;...
Starch and sucrose metabolism	1.74	3.39e-2	25/36 (69.44%)	UGP2;GYS1;PYGB;...
Mucin type O-glycan biosynthesis	1.70	4.68e-2	20/36 (55.56%)	GALNT6;GALNT2;ST6GALNAC2;...
Long-term potentiation	1.69	4.84e-2	61/67 (91.04%)	CALML3;CALML5;ITPR2;...
Citrate cycle (TCA cycle)	1.68	4.90e-2	30/30 (100%)	CS;ACO1;SDHA;...
Dopaminergic synapse	1.67	4.76e-2	115/132 (87.12%)	GNAS;CALML3;CALML5;...
Viral protein interaction with cytokine and cytokine re...	-1.74	4.73e-2	84/100 (84%)	CCL21;TNFRSF1B;PPBP;...
Porphyrin and chlorophyll metabolism	-1.77	4.28e-2	23/43 (53.49%)	ALAS2;CPOX;HMBS;...
Systemic lupus erythematosus	-2.03	0.00e+0	45/135 (33.33%)	HLA-DOA;CD80;FCGR3B;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Hide ▲

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼